{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:35:33Z","timestamp":1772728533480,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A2C1102300 and NRF-2016M3A9E4947797"],"award-info":[{"award-number":["NRF-2020R1A2C1102300 and NRF-2016M3A9E4947797"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in women worldwide, with an overall 5 year survival rate below 30%. The low survival rate is associated with the persistence of cancer stem cells (CSCs) after chemotherapy. Therefore, CSC-targeting strategies are required for successful EOC treatment. Pan-human epidermal growth factor receptor 4 (HER4) and L-type calcium channels are highly expressed in ovarian CSCs, and treatment with the pan-HER inhibitor poziotinib or calcium channel blockers (CCBs) selectively inhibits the growth of ovarian CSCs via distinct molecular mechanisms. In this study, we tested the hypothesis that combination treatment with poziotinib and CCBs can synergistically inhibit the growth of ovarian CSCs. Combined treatment with poziotinib and manidipine (an L-type CCB) synergistically suppressed ovarian CSC sphere formation and viability compared with either drug alone. Moreover, combination treatment synergistically reduced the expression of stemness markers, including CD133, KLF4, and NANOG, and stemness-related signaling molecules, such as phospho-STAT5, phospho-AKT, phospho-ERK, and Wnt\/\u03b2-catenin. Moreover, poziotinib with manidipine dramatically induced apoptosis in ovarian CSCs. Our results suggest that the combinatorial use of poziotinib with a CCB can effectively inhibit ovarian CSC survival and function.<\/jats:p>","DOI":"10.3390\/ijms21197379","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T10:46:17Z","timestamp":1601981177000},"page":"7379","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness"],"prefix":"10.3390","volume":"21","author":[{"given":"Heejin","family":"Lee","sequence":"first","affiliation":[{"name":"New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Chumbok-ro, Dong-gu, Daegu 41061, Korea"},{"name":"BK21 Plus KNU Creative BioResearch Group, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu 41566, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Chumbok-ro, Dong-gu, Daegu 41061, Korea"},{"name":"BK21 Plus KNU Creative BioResearch Group, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu 41566, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-1615","authenticated-orcid":false,"given":"Dong-Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"BK21 Plus KNU Creative BioResearch Group, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu 41566, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyun","family":"Min","sequence":"additional","affiliation":[{"name":"New Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Chumbok-ro, Dong-gu, Daegu 41061, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4331\/wjbc.v1.i7.209","article-title":"Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action","volume":"1","author":"Itamochi","year":"2010","journal-title":"World J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","article-title":"Ovarian cancer: A focus on management of recurrent disease","volume":"3","author":"Herzog","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: Premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/aps.2013.27","article-title":"Understanding and targeting cancer stem cells: Therapeutic implications and challenges","volume":"34","author":"Chen","year":"2013","journal-title":"Acta. Pharmacol. Sin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"941876","DOI":"10.1155\/2011\/941876","article-title":"Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis","volume":"2011","author":"Morrison","year":"2011","journal-title":"J. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lee, H., Kim, J.W., Kim, D.K., Choi, D.K., Lee, S., Yu, J.H., Kwon, O.B., Lee, J., Lee, D.S., and Kim, J.H. (2020). Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072327"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbrc.2020.03.046","article-title":"Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway","volume":"526","author":"Lee","year":"2020","journal-title":"Biochem Biophys Res. Commun"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2146\/news080074","article-title":"FDA approves i.v. calcium-channel blocker","volume":"65","author":"Thompson","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2011.01.010","article-title":"Antitumor activity of HM781\u201336B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer","volume":"302","author":"Nam","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/ijc.26276","article-title":"Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models","volume":"130","author":"Cha","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Delou, J.M.A., Souza, A.S.O., Souza, L.C.M., and Borges, H.L. (2019). Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 8.","DOI":"10.3390\/cells8091013"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/stem.2279","article-title":"Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism","volume":"34","author":"Seo","year":"2016","journal-title":"Stem Cells"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/01.sla.0000145964.08365.01","article-title":"Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases?","volume":"240","author":"Adam","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fu, Z., Ma, K., Dong, B., Zhao, C., Che, C., Dong, C., Zhang, R., Wang, H., Wang, X., and Liang, R. (2019). The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. BMC Complement. Altern. Med., 19.","DOI":"10.1186\/s12906-019-2614-5"},{"key":"ref_25","first-page":"155","article-title":"Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: A retrospective analysis","volume":"4","author":"Eckmann","year":"2011","journal-title":"Gastrointest Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1179299X19860815","DOI":"10.1177\/1179299X19860815","article-title":"Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1349-7006.2010.01556.x","article-title":"Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: A novel insight into the molecular pathogenesis of ovarian epithelial carcinoma","volume":"101","author":"Motohara","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2013.12.001","article-title":"Ovarian cancer stem cells: Are they real and why are they important?","volume":"132","author":"Shah","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Motohara, T., and Katabuchi, H. (2019). Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance. Cancers (Basel), 11.","DOI":"10.3390\/cancers11070907"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: Targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: Navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Xu, F., Na, L., Li, Y., and Chen, L. (2020). Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci., 10.","DOI":"10.1186\/s13578-020-00416-0"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1096\/fj.201801690R","article-title":"Overexpression of ERBB4 rejuvenates aged mesenchymal stem cells and enhances angiogenesis via PI3K\/AKT and MAPK\/ERK pathways","volume":"33","author":"Liang","year":"2019","journal-title":"FASEB J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Antal, L., and Martin-Caraballo, M. (2019). T-type Calcium Channels in Cancer. Cancers (Basel), 11.","DOI":"10.3390\/cancers11020134"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7379\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:16:56Z","timestamp":1760177816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":37,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197379"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197379","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]}}}